Trial Profile
A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic HCV GT1, GT4 and GT6 Infection With Inherited Blood Disorders With and Without HIV Co-Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms C-EDGE IBLD
- Sponsors Merck Sharp & Dohme Corp.
- 19 Feb 2019 Results of integrated analysis of data from 12 international phase 2/3 clinical trials(NCT01717326,NCT01932762,NCT02092350,NCT02105467,NCT02105662,NCT02105688,NCT02105701,NCT02115321,NCT02203149,NCT02251990,NCT02252016 and NCT02358044) assessing safety and efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis C Virus Genotypes 1 and 4 Infection published in the Journal of Gastroenterology and Hepatology
- 26 Apr 2018 Results of retrospective analysis of black participants receiving elbasvir/grazoprevir (EBR/GZR) in nine phase 2/3 clinical trials (C-SURFER (NCT02092350); C-EDGE COINFECTION (NCT02105662) ; C-EDGE TREATMENT-NAIVE (NCT02105467/protocol PN060) ; C-EDGE TREATMENT-EXPERIENCED (NCT02105701/protocol PN068) ; C-WORTHY (NCT01717326/protocol PN035); C-EDGE IBLD (NCT02252016/protocol PN065), and C-EDGE COSTAR (NCT02105688/protocol PN062)) published in the American Journal of Gastroenterology
- 03 Mar 2017 Results analysing the efficacy and safety published in the Hepatology.